Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)
State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI's under-20x earnings multiple and diversified holdings support a constructive outlook.
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?
At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.
Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed.
XBI: A "Hidden" ETF Up +70% In 1 Year.
State Street SPDR S&P Biotech ETF (XBI) has delivered over 75% 1-year performance, driven by equal-weight exposure to volatile small- and mid-cap biotech stocks. XBI's high beta profile offers strong upside in bullish healthcare cycles but exposes investors to elevated annualized volatility of around 26%. Current valuations for XBI are relatively stretched, with forward P/E at 17x and earnings growth expectations below 3%, making new entry less attractive.
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded.
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
The biotech industry has been a robust roller-coaster over the last half decade.
